TABLE OF CONTENTS
Volume 1, Issue 1 (July 2000)
Editorial
Top of pagePapers
Corporate identity cues: The significance of the sales force
E Dimopoulou and C Fill
J Med Market 1: 9-19; doi:10.1057/palgrave.jmm.5040002
The 'industry' perspective on GP prescribing — How good is it?
P Stern
J Med Market 1: 20-32; doi:10.1057/palgrave.jmm.5040003
The Russian pharmaceutical market after the crisis: An insider's view
V Anashkina
J Med Market 1: 33-39; doi:10.1057/palgrave.jmm.5040004
Strategic market segmentation: An opportunity to integrate medical and marketing activities
J MacLennan and D MacKenzie
J Med Market 1: 40-52; doi:10.1057/palgrave.jmm.5040005
Reimbursement and pricing of medical devices in Germany
J M Schmitt
J Med Market 1: 53-58; doi:10.1057/palgrave.jmm.5040006
NICE: Opportunity or threat?
G Camps-Walsh
J Med Market 1: 59-65; doi:10.1057/palgrave.jmm.5040007
What influences prescriptions by physicians? A study of subjective norm, perceived behavioural control and volition
L van der Geer and P Kangis
J Med Market 1: 66-73; doi:10.1057/palgrave.jmm.5040008
Finding and winning venture capital for medical start-ups: A Canadian model
H MacNaught
J Med Market 1: 74-79; doi:10.1057/palgrave.jmm.5040009
Book Reviews
R&D Strategies in the Medical Device and Diagnostics Industry
Hugh McNaught
J Med Market 1: 87; doi:10.1057/palgrave.jmm.5040011
Scrip's Guide to Successful Pharmaceutical Marketing
Philip Stern
J Med Market 1: 88-89; doi:10.1057/palgrave.jmm.5040012
From Quackery to Credibility – Unconventional Healthcare in the Era of High-Tech Medicine
Magnus Jaderberg
J Med Market 1: 90-91; doi:10.1057/palgrave.jmm.5040013
Global Pharmaceutical Pricing
Michael Friedman
J Med Market 1: 92-93; doi:10.1057/palgrave.jmm.5040014
